Phaseline

Targets › KEAP1

KEAP1 (Kelch-like ECH-associated protein 1): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 3 Phase 2, 1 Phase 3; Neurology, Ophthalmology, Oncology; next expected readout Apr 2027.

Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that regulates the response to oxidative stress by targeting NFE2L2/NRF2 for ubiquitination. KEAP1 acts as a key sensor of oxidative and electrophilic stress: in normal conditions, the BCR(KEAP1) complex mediates ubiquitination and degradation of NFE2L2/NRF2, a transcription factor regulating expression of many cytoprotective genes. (UniProt, Q14145)

Open in Phaseline: the race on KEAP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Hospital, MontpellierDimethyl Fumarate
Kelch-like ECH-associated protein 1 inhibitor
KEAP1Phase 3Relapsing-Remitting Multiple Sclerosis (RRMS)Jun 2031
Assistance Publique - Hôpitaux de ParisDimethyl Fumarate
Kelch-like ECH-associated protein 1 inhibitor
KEAP1Phase 2Age-related Macular Degeneration (AMD)Apr 2027
NYU Langone HealthDRP-104
Glutamine antagonist
NFE2L2, KEAP1Phase 2Non Small Cell Lung CancerOct 2027
Medical University of Lodzdimethyl fumarate
Kelch-like ECH-associated protein 1 inhibitor
KEAP1Phase 2MCIDec 2027

Conditions

Age-related Macular Degeneration (AMD) (1) MCI (1) Non Small Cell Lung Cancer (1) Relapsing-Remitting Multiple Sclerosis (RRMS) (1)

Modalities

small molecule (3), mixed (1)

Companies

Assistance Publique - Hôpitaux de Paris (1) Medical University of Lodz (1) NYU Langone Health (1) University Hospital, Montpellier (1)

Related targets

NFE2L2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.